Evidence mapPaperPMID 40807245Full record

ReviewMolecules (Basel, Switzerland)2025

Current Status of the Application of Antimicrobial Peptides and Their Conjugated Derivatives.

Marcel Lí Del Olmo, Cecilia Andreu

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marcel Lí Del OlmoDepartament de Bioquímica i Biologia Molecular, Universitat de València (UVEG), Doctor Moliner 50, 46100 Burjassot, València, Spain.ORCID 0000-0002-8682-6369
Cecilia AndreuDepartment de Química Orgànica, Universitat de València (UVEG), Vicent Andrés Estellés, sn, 46100 Burjassot, València, Spain.ORCID 0000-0003-2324-9944

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A significant issue in healthcare is the growing prevalence of antibiotic-resistant strains. Therefore, it is necessary to develop strategies for discovering new antibacterial compounds, either by identifying natural products or by designing semisynthetic or synthetic compounds with this property. In this context, a great deal of research has recently been carried out on antimicrobial peptides (AMPs), which are natural, amphipathic, low-molecular-weight molecules that act by altering the cell surface and/or interfering with cellular activities essential for life. Progress is also being made in developing strategies to enhance the activity of these compounds through their association with other molecules. In addition to identifying AMPs, it is essential to ensure that they maintain their integrity after passing through the digestive tract and exhibit adequate activity against their targets. Significant advances are being made in relation to analyzing various types of conjugates and carrier systems, such as nanoparticles, vesicles, hydrogels, and carbon nanotubes, among others. In this work, we review the current knowledge of different types of AMPs, their mechanisms of action, and strategies to improve performance.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesAnimalsHumansNanoparticlesAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial Cationic PeptidesAntimicrobial Peptidesantibioticsantimicrobial peptide conjugatesantimicrobial peptide nanostructuresantimicrobial peptidesantimicrobial resistance

Identifiers

PMID40807245
PMCPMC12348590

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.